Compare · OM vs SLNO
OM vs SLNO
Side-by-side comparison of Outset Medical Inc. (OM) and Soleno Therapeutics Inc. (SLNO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both OM and SLNO operate in Biotechnology: Electromedical & Electrotherapeutic Apparatus (Health Care), so they compete in similar markets.
- SLNO is the larger of the two at $2.76B, about 32.4x OM ($85.3M).
- Over the past year, OM is down 76.3% and SLNO is down 31.2% - SLNO leads by 45.0 points.
- SLNO has been more active in the news (42 items in the past 4 weeks vs 14 for OM).
- OM has more recent analyst coverage (13 ratings vs 12 for SLNO).
- Company
- Outset Medical Inc.
- Soleno Therapeutics Inc.
- Price
- $4.59-9.47%
- $53.02+0.08%
- Market cap
- $85.3M
- $2.76B
- 1M return
- +5.88%
- +0.76%
- 1Y return
- -76.27%
- -31.24%
- Industry
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2020
- 2014
- News (4w)
- 14
- 42
- Recent ratings
- 13
- 12
Outset Medical Inc.
Outset Medical, Inc., a medical technology company, develops a hemodialysis system for dialysis. It offers Tablo Hemodialysis System, which comprises of a compact console with integrated water purification, on-demand dialysate production, and software and connectivity capabilities for dialysis care in acute and home settings. The company was formerly known as Home Dialysis Plus, Ltd. and changed its name to Outset Medical, Inc. in January 2015. Outset Medical, Inc. was incorporated in 2003 and is headquartered in San Jose, California.
Soleno Therapeutics Inc.
Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Controlled-Release (DCCR), a once-daily oral tablet for the treatment of Prader-Willi Syndrome (PWS), is being evaluated in a Phase III clinical development program. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics has collaboration with Vanderbilt University to discover and develop next generation K(ATP) channel activators for the treatment of rare diseases. Soleno Therapeutics, Inc. was incorporated in 1999 and is headquartered in Redwood City, California.
Latest OM
- Outset Medical Inc. filed SEC Form 8-K: Leadership Update
- SEC Form SD filed by Outset Medical Inc.
- Outset Medical Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
- Chair and CEO Trigg Leslie sold $12,746 worth of shares (3,445 units at $3.70), decreasing direct ownership by 3% to 98,874 units (SEC Form 4) to satisfy tax liability
- EVP Operations R&D & Service Nash Marc sold $5,853 worth of shares (1,582 units at $3.70), decreasing direct ownership by 4% to 38,393 units (SEC Form 4) (tax withholding)
- General Counsel Brottem John L. sold $9,761 worth of shares (2,638 units at $3.70), decreasing direct ownership by 8% to 30,277 units (SEC Form 4) (for withholding tax)
- Amendment: SEC Form SCHEDULE 13G/A filed by Outset Medical Inc.
- Large owner Leonard Braden Michael exercised 323,000 in-the-money shares at a strike of $5.00 (SEC Form 4)
- SEC Form 144 filed by Outset Medical Inc.
- Amendment: SEC Form SCHEDULE 13G/A filed by Outset Medical Inc.
Latest SLNO
- SEC Form 15-12G filed by Soleno Therapeutics Inc.
- SEC Form EFFECT filed by Soleno Therapeutics Inc.
- SEC Form POS AM filed by Soleno Therapeutics Inc.
- SEC Form AW filed by Soleno Therapeutics Inc.
- Officer Yen Kristen returned 37,639 shares to the company, closing all direct ownership in the company (SEC Form 4)
- Director Volck Birgitte returned 17,536 shares to the company, closing all direct ownership in the company (SEC Form 4)
- Director Sinclair Andrew returned 10,491 shares to the company, closing all direct ownership in the company (SEC Form 4)
- Director Pauls Matthew returned 10,491 shares to the company, closing all direct ownership in the company (SEC Form 4)
- Chief Business Officer Norrett Kevin returned 17,786 shares to the company, closing all direct ownership in the company (SEC Form 4)
- Chief Commercial Officer Manning Meredith returned 64,507 shares to the company, closing all direct ownership in the company (SEC Form 4)